Meningitis B: the vaccine debate

So another week where I’ve felt compelled to cover a topic in the news. This time meningitis. I struggled a little with this one, as it’s clearly an emotive subject. I actually came away after writing the piece with a slightly different opinion – I had my own internal vaccine debate.

On 14 February 2016, a two-year old girl in Kent died of meningococcal septicaemia. The cause was meningitis B. It acted as a reminder to the British public that meningitis can and does kill. But, should everyone be vaccinated against meningitis B, what about the other strains, and what are the risks of getting the disease? Well, here goes.

Meningitis: an overview

Meningitis is the swelling of the meninges (a protective layer around the brain). It is usually caused by a bacterial or viral infection. Many different bacteria can cause meningitis, including, but not limited to:

  • Haemophilus influenzae type B or HiB (part of the UK childhood vaccination schedule)
  • Streptococcus pneumoniae (part of the childhood vaccination schedule)
  • Mycobacterium tuberculosis (causes TB and the vaccine is offered to those at increased risk of infection)
  • In newborns a variety of pathogens, including group B Streptococcus, Listeria, E. coli
  • Neisseria meningitidis (split into several serogroups, see below)

Different types of meningitis may have different severities, but bacterial meningitis can be fatal, or have lifelong consequences.

Meningitis A, B, C, W, Y, Z

Meningitis A, B, C, W, Y and Z are all caused by Neisseria meningitidis. Currently children are offered a vaccine against meningitis C as part of the UK childhood vaccination schedule, and then a vaccine against A, C, W and Y as teenagers (important as there has been an increase in Men W cases in this age group recently).

As a child, I remember several children contracting meningitis C. Just before university I was vaccinated as part of the Meningitis C vaccination campaign, and since then cases have reduced dramatically.

Cases of Meningitis B, C and W in England and Wales (years run July-June)

The vaccination for Meningitis B has been longer in the making, due to some specific properties of the bacteria. But, finally, in 2015 a vaccine was approved for the UK childhood vaccination schedule (there was a lot of wrangling over price to try to make it cost-effective to the NHS).

Meningitis B: The vaccine and the cases

Looking at the graph above, you can see that Meningitis B account for the majority of cases of meningitis caused by Neisseria meningitidis in England and Wales. It accounted for 80% of cases in infants and 86% in toddlers (see the latest report from Public Health England). Case numbers are still small however, with 418 cases reported from July 2014 to June 2015, with 25 deaths. To put that into perspective, there were an average of 224 deaths due to childhood cancer in England and Wales each year from 2009-2011. Hopefully now that children are being vaccinated against Meningitis B, this will reduce even further.

Cases of Meningitis B by age group in England and Wales, July 2014 to June 2015

Why no catch-up campaign?

One thing the death of the little girl last week has highlighted, is that unlike the Meningitis C vaccination campaign 15 years ago, the Meningitis B vaccination strategy has no catch up programme (well, almost none). She was two years old, and therefore born before the vaccination campaign had started, and like all other two year olds, would not receive the vaccination as part of the childhood vaccination schedule. Since her death, a petition to give the vaccination to children up to 11 has reached 636,000 signatures, and is still increasing.

But why has the government not implemented this already? Well, I don’t know. But here are some possible reasons. Firstly, it is expensive. The Joint Committee on Vaccines and Immunisations (JCVI) position statement shows that it really didnt appear to be cost-effective. The problem is that the disease is so rare, that even if the vaccine was cheap, it was unlikely to be cost-effective in the eyes of the NHS. I know this is of little reassurance to parents, or individuals affected, but the NHS can’t fund everything.

Secondly, the highest risk is in children under the age of one. I know my graph shows more cases in those aged one to four, but there are more children in that age group. Proporionally, most of the cases and deaths are in the under ones. There’s a much better graph here.

Finally, and perhaps most importantly, there is still not very good data on how long protection will last. Even the manufacturer reports a reduction in protection after just eight months. [Update: I’ve found one study reporting between 41 and 75% of children were protected areas 3yrs 4 months. Though only small numbers, this suggests a preschool booster would be required to protect children to age 5, and possibly more to protect through childhood. The scientific consensus seems to be we just don’t know how long the vaccine will protect people at the moment]. If this turns out to be the case, and protection is short-lived, it may be that children vaccinated in infancy will not be protected by the time that they are three or five, for example. By this time, they will have got past the most risky period, but it has major implications for any catch-up campaign. If the vaccine is expensive for two or three doses, it would be prohibitively so if you have to vaccinate every child every few years to ensure they are protected up until 11. I suspect if the petition is considered, it will be decided that the vaccination is currently too expensive and with too many uncertainties to implement a catch-up campaign.

Update: MPs have view heard evidence from parents, charities, scientists, doctors and public health experts. Both charities and scientists were in agreement that after under ones those under five years of age are the most at risk. However, limitations in what we know about the vaccine and about how we calculate cost-effectiveness were raised. While research is ongoing into these, I got the impression that any change to the age groups vaccinated would be after these areas are better understood. It felt generally optimistic though. Here’s a quick run down of some of the issues discussed.

Next month the issue will be debated in parliment.

What would I do?

Well. I can be a bit needle-happy with the kids at the best of times, so I was going to get both my children vaccinated privately (a relatively expensive option). However, there is currently a shortage of Meningitis B vaccine for the private market (those who are eligible for the vaccine should be fine). In the meantime, my children are getting older. While Boybug is still younger than the girl that died last week, the chances of either of them contracting Meningitis B remain low, and are decreasing. That, teamed with my new knowledge that we do not know how well the vaccine is going to perform, means I may hold off. For what it’s worth, I signed the petition. In an ideal world, I believe the vaccine should be available to those that want it. However, I think it’s unlikely that this will happen, and now I’ve looked into it a bit further I don’t think the science is yet there to support a catch-up campaign up to age 11. That might be quite a controversial view-point, and my view may change as we learn more about how the vaccine is performing.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s